Cephalon Acquires Swiss Pharmaceutical Company Mepha
Cephalon said that the purchase price paid at closing, inclusive of certain closing adjustments, was CHF662.4m. The purchase price is also subject to further post-closing working capital and
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.